EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Allergy Therapeutics plc (AGYTF) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Allergy Therapeutics plc $0.06, price $0.15, upside -60.0%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home United Kingdom

AT Allergy Therapeutics plc logo Thin data Jun 23, 2026

Allergy Therapeutics plc

AGYTF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0600 · Strongly overvalued (−60.0%)
!Quality 32/100
!Weak Growth (revenue 5y −0.7 %/yr)
!Loss-making · -84.1% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Allergy Therapeutics plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.2481 $0.0000 Fair Value $0.0600 Jul 2015 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $0.0000 – $0.2481 · fair‑value band $0.0400 – $0.0700 · the $0.1500 price screens above the $0.0600 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Allergy Therapeutics in your weekly email

Every Wednesday you see whether Allergy Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.

Show more

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Stock analysis

Allergy Therapeutics plc (AGYTF) currently trades at $0.1500, while our model-based Fair Value estimate is $0.0600, 60.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: $0.0400 (bear) to $0.0700 (bull), the price of $0.1500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Allergy Therapeutics plc reported revenue of £75.6M in FY2025 versus £84.3M in FY2021, a compound −2.7%/yr. Reported net income was −£55.1M in FY2025.

Key figures

Market cap $950M · P/S ratio 16.6 · EPS (TTM) $−0.0100 · Net margin −72.9% · Return on equity −369% · Return on assets (EBIT) −33.5% · Operating margin −31.4% · Revenue (TTM) £57.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 76% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −60%, AGYTF screens richer than that median.

Notify me when AGYTF reaches fair value

Put AGYTF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 32/100

Of which business quality 34 · Market factors (momentum, volatility) 82

Profitability 44
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 93
Disciplined investing over empire-building
Low Volatility 73
Calm price path (market factor)
Momentum 78
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+36.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.6% (2020) → −37.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AGYTF screens overvalued: fair value 60% below the price. Compare with Merck KGaA →

Compare Allergy Therapeutics plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −29.6% · Bottom 25%
Net margin (TTM) −84.1% · Bottom 25%
Operating margin (TTM) −31.4% · Bottom 25%
Growth and dividend
Revenue growth 6.6% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 16.58× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)33 · sector 24
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Allergy Therapeutics plc · Fair Value
$0.0600 −60%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Allergy Therapeutics plc Fair Value". https://www.fairvalue-calculator.com/stock/AGYTF

Frequently asked questions

Is Allergy Therapeutics plc (AGYTF) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.0600 versus a price of $0.1500, about −60% upside (overvalued).
What is the fair value of AGYTF?
Our model-based fair value for Allergy Therapeutics plc is $0.0600 (as of Jun 23, 2026), built from audited fundamentals. The current price: $0.1500.
What is the quality score of AGYTF?
Allergy Therapeutics plc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Allergy Therapeutics plc (AGYTF)?
Our model-based price target is the fair value of $0.0600 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $0.0400, optimistic scenario $0.0700. It is a calculation from audited fundamentals, not an analyst target.
What is the Allergy Therapeutics plc stock forecast for 2026?
Our models put fair value at $0.0600, about −60% upside versus a price of $0.1500 (overvalued). Cautious scenario $0.0400, optimistic scenario $0.0700. The calculation is refreshed regularly with new filings.
What is the revenue of Allergy Therapeutics plc (AGYTF)?
Allergy Therapeutics plc reported trailing-twelve-month revenue of about £57.3M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Allergy Therapeutics plc (AGYTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Allergy Therapeutics plc it is $0.0600 per share (as of Jun 23, 2026), against a price of $0.1500. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Allergy Therapeutics plc stock overvalued or undervalued in 2026?
As of Jun 23, 2026, AGYTF trades above its calculated fair value: price $0.1500, fair value $0.0600, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AGYTF?
No. The price is what the market pays today ($0.1500); the fair value is what the company's own numbers justify ($0.0600). For Allergy Therapeutics plc the two are $0.0900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Allergy Therapeutics plc worth?
The market values Allergy Therapeutics plc at about $950M (market capitalisation, as of Jun 23, 2026). Per share that is $0.1500; our models calculate a fair value of $0.0600 per share.
What do the bullish and bearish scenarios say about AGYTF?
Our models span a range for Allergy Therapeutics plc: cautious scenario $0.0400, base $0.0600, optimistic $0.0700 per share (as of Jun 23, 2026, price $0.1500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Allergy Therapeutics plc (AGYTF)?
Balance-sheet figures for Allergy Therapeutics plc (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is AGYTF from its 52-week high?
Allergy Therapeutics plc trades at $0.1500, at its 52-week high of $0.1500 and 76% above the low of $0.0850 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0600 is for.
Which stocks are comparable to Allergy Therapeutics plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Allergy Therapeutics plc stock attractive at the current price?
The data as of Jun 23, 2026: price $0.1500, calculated fair value $0.0600 (−60%), Quality Score 32/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AGYTF calculated?
We run Allergy Therapeutics plc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Allergy Therapeutics plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Allergy Therapeutics plc (AGYTF)?
The closing price on Oct 1, 2026 was $0.1500. Our model-based fair value is $0.0600, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Allergy Therapeutics plc right now?
The price sits above even our optimistic bull case ($0.0700). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Allergy Therapeutics plc

How large is the market capitalisation of Allergy Therapeutics plc (AGYTF)?
The market capitalisation of Allergy Therapeutics plc is $950M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Allergy Therapeutics plc (AGYTF)?
The price-to-sales ratio of Allergy Therapeutics plc is 16.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Allergy Therapeutics plc (AGYTF)?
Earnings per share at Allergy Therapeutics plc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Allergy Therapeutics plc (AGYTF)?
The net margin of Allergy Therapeutics plc is −72.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Allergy Therapeutics plc (AGYTF)?
The return on equity (ROE) of Allergy Therapeutics plc is −369% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Allergy Therapeutics plc (AGYTF)?
On an EBIT basis the return on assets of Allergy Therapeutics plc is −33.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Allergy Therapeutics plc (AGYTF)?
The operating margin of Allergy Therapeutics plc is −31.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Allergy Therapeutics plc (AGYTF)?
Revenue at Allergy Therapeutics plc is growing +6.6% versus a year earlier (3y avg +1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Allergy Therapeutics plc (AGYTF)?
Earnings per share at Allergy Therapeutics plc are growing −55.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Allergy Therapeutics plc (AGYTF) generate?
The free cash flow of Allergy Therapeutics plc is −£43.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Allergy Therapeutics plc (AGYTF) carry?
The net debt of Allergy Therapeutics plc is £64.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Allergy Therapeutics plc in the live analysis

One click puts Allergy Therapeutics plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.